{"id":"W2138077952","doi":"10.1016/s0140-6736(08)61206-4","title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1068,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk; Amylin Pharmaceuticals; Eli Lilly and Company","keywords":"Exenatide; Medicine; Type 2 diabetes; Open label; Internal medicine; Diabetes mellitus; Randomized controlled trial; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1022408823819575,"score_gpt":0.3476723919092116,"score_spread":0.2454315095272541,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}